Starting 9 November, a 30% ceiling on trade margins will apply to 137 non-scheduled anti-cancer drug formulations under a ruling by the National Pharmaceutical Pricing Authority, a move the authority says is expected to bring down out-of-pocket costs for patients receiving cancer treatment in India. Retail prices on individual medicines could fall by as much as 70%, with the precise reduction tied to each product's existing price point.

Pricing markups along the pharmaceutical supply chain would be brought down under the policy, with households facing drug costs projected to see some easing of that financial burden. Under Paragraph 19 of the Drugs (Prices Control) Order 2013, the NPPA has applied the Trade Margin Rationalisation mechanism as the vehicle for implementing this latest pricing measure.

A 30% ceiling on trade margins will apply across 137 anti-cancer drug formulations that have been officially notified under the pricing framework. The adjusted pricing structure is set to come into force on 9 November 2026, as outlined in a statement from the Ministry of Chemicals and Fertilizers.

The 70% figure marks the outer boundary of what savings could theoretically reach, rather than a uniform reduction applied to every medicine on the list. How much buyers actually save will depend on the price point and distribution margins tied to each individual formulation.

Spanning 137 anti-cancer drug formulations that fall outside scheduled pricing, the directive draws on recommendations put forward by a specialist panel assembled through the Directorate General of Health Services. The panel brings together professionals from oncology, broader medical practice, hospital administration, and government. Periodic updates to the list were outlined in a statement from the ministry.

Coverage for oncology treatments in India does not extend automatically to every available drug. Those whose prescriptions may fall within the scope of the updated regulations are advised to consult the relevant official register to verify their specific formulation's status.

The new ruling builds on prior steps taken by the NPPA to bring down the cost of oncology treatments. A 2019 policy capped trade margins on 42 oncology drugs at 30%, covering 526 brand variants and bringing listed retail prices down by as much as 90%. Under the 2026 plan, a margin ceiling will apply to 137 anti-cancer medicines that currently fall outside scheduled pricing, with retail costs projected to drop by varying amounts up to 70%, depending on where individual product prices currently stand.

The two policies differ in the breadth of their reach. How much a product is affected will vary based on its particular makeup and the price point at which it currently sits.

Updated drug prices are accessible to the public through two official channels — the NPPA's dedicated website and a government-backed mobile application called Pharma Sahi Daam. Updated pricing schedules from pharmaceutical companies are to be distributed to both retailers and hospitals under the new requirements.

Patients who find that a pharmacy or hospital is billing above the officially notified rate have the option to request an explanation and raise the matter with the appropriate drug-control authority. From 9 November, both pharmacy retailers and hospital outlets are required to adopt the newly adjusted pricing on notified formulations and display those updated figures where customers can see them. Under the ministry's directive, updated pricing details are also to be displayed prominently on each hospital's website.

Oversight of adherence to drug regulations has been assigned to state-level controllers, covering the full supply chain from manufacturers and distributors through to pharmacies, hospitals, and other medical institutions. According to the NPPA, the policy targets profit margins deemed excessive while leaving room for legitimate manufacturing revenues and avoiding any disruption to supply. Orders went out to drug manufacturers to maintain output and supply chains for the listed formulations at their current levels. Keeping cancer treatments accessible for patients and reducing the cost of those therapies are stated as the central objectives of the plan.